The cost of insulin remains a significant point of contention in American healthcare, a decade after the drug became a primary symbol of rising pharmaceutical prices. Public concern intensified following the 2017 death of Alec Smith, who died after rationing his insulin due to high costs. This tragedy, combined with the fact that the original patent for insulin was sold for only $1 to ensure public access, has fueled ongoing criticism regarding the commercialization of the medication.

While there have been recent policy initiatives aimed at capping insulin costs for specific groups, such as Medicare beneficiaries, critics argue that these measures do not go far enough. Vox reports that millions of patients still face financial hardship and health risks associated with the high price of the drug. The core of the debate involves a disagreement over the effectiveness of current interventions; some policymakers highlight the progress made in capping out-of-pocket costs, while advocates and patients emphasize that the list price of insulin remains prohibitively high for many uninsured or underinsured individuals. The situation highlights a persistent gap between legislative attempts to lower costs and the actual financial burden experienced by those who rely on insulin to survive.